Global pharmaceutical company Allergan has confirmed that it has received Food and Drug Administration (FDA) approval to market JUVÉDERM VOLLURE XC for the correction of moderate to severe facial wrinkles and folds in the US.
Dermatology company Galderma has announced that its hyaluronic acid dermal filler Restylane Silk has received approval by the US Food and Drug Administration (FDA) for lip augmentation with the use of a small blunt tip cannula.
Two of the industry’s leading companies could become one if a multi-million dollar bid by Galderma to acquire Q-Med goes ahead. In a joint venture between L’Oreal and Nestle. Galderma, the makers of Azzalure®, launched a reported $970 million bid for the Swedish manufacturer of Restylane® at the end of 2010.
Global aesthetic manufacturer Teoxane Laboratories has announced that the US Food and Drug Administration (FDA) has approved three of its dermal fillers.
A multi-platform technology aimed at providing long-lasting skin tightening has been launched in the UK.
International pharmaceutical company Galderma has launched a new hologram on all packaging across the entire Restylane portfolio of Non-Animal Stabilised HA (NASHA) and Optimal Balance Technology (OBT) products, as well as the Skinboosters range to provide practitioners with further assurance that the products are original.
The US Food and Drug Administration (FDA) has approved hyaluronic acid dermal filler Restylane Lyft for cheek augmentation and the correction of age-related mid-face contour deficiencies via small blunt tip cannula in patients over the age of 21.
Galderma Laboratories has announced that its full prescription-strength Differin Gel has been approved by the US Food and Drug Administration (FDA) for an over-the-counter (OTC) treatment for acne.
A study conducted by Dr Sebasitian Torres in Italy suggests patients were highly satisfied with their results after being treated with a new stabilised hyaluronic acid dermal filler by Intraline.
Due to unforeseen circumstances, The Anatomy of the Smile Webinar sponsored by pharmaceutical company Galderma has been postponed until March 11.